Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
About Regado Biosciences
Regado Biosciences is pioneering a new therapeutic field with the creationand development of two-component drug systems, comprising an aptamertherapeutic that can be controlled directly by its specific and matchedreversal agent. Regado's technology is designed to give physicians theability to directly control and titrate each system's therapeutic effect.Enhanced control and flexibility allow physicians to meet the individual needsof patients independent of the setting. Regado is focusing its discovery anddevelopment efforts on acute care injectable antithrombotics, a multi-billiondollar market in need of therapeutics with improved safety profiles and agreater degree of therapeutic control.
Current investors in Regado include Domain (Princeton, NJ), QuakerBioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton AdvantageLife Sciences Fund (New York, NY), as well as individual investors, includingRobert Kierlin.
SOURCE Regado Biosciences
You May Also Like